May 10, 2019 News by Ana Pena PhD #AANAM – RRMS Patients Switching to Lemtrada Report Greater Satisfaction with Treatment and Improvements in Quality of Life Patients with relapsing-remitting multiple sclerosis (RRMS) who switched to infusions with Sanofi Genzymeās Lemtrada (alemtuzumab) report increased satisfaction with treatment and improvements in health-related quality of life, according to…
April 29, 2019 News by Santiago Gisler Relapsing MS Patients Highly Satisfied with Aubagio’s Efficacy and Ease of Use, Global Clinical Study Finds High levels of satisfaction with the efficacy and convenience ofĀ Aubagio (teriflunomide), an oral treatment for relapsingĀ multiple sclerosis (MS), were reported by patients across the U.S. and 13 other countries, a post-hoc analysis of data from a real-world Phase 4 study found. The study “Teriflunomide real-world evidence: Global…
August 17, 2018 News by Marta Figueiredo, PhD Most MS Patients OK With Intravenous Treatment Conditions, Study Suggests Most patients with multiple sclerosis (MS) are satisfied with the conditions of their intravenous therapy (administered directly into the bloodstream) and are very aware of the therapy’s safety,Ā according to a small Macedonian study. Also, establishing a specialized infusion center would substantially increase intravenous treatment satisfaction and adherence. The study, ā…
May 24, 2018 News by Ashraf Malhas, PhD Gilenya Tied to Treatment Satisfaction, Quality of Life in MS Patients Treatment with Gilenya (fingolimod) is associated with treatment satisfaction, which, in turn, is linked to a better quality-of-life in patients withĀ relapsing-remitting multiple sclerosis (RRMS), a study has found. Gilenya, an oral disease-modifying treatment (DMT) for RRMS developed by Novartis, has been available in France since 2011. Studies have…
September 30, 2016 News by Alice MelĆ£o, MSc Satisfaction with MS Therapy Influenced by Doctor-Patient Communication, Study Finds A study published in the BMC Neurology journal emphasizedĀ that clear and regularĀ communication between physicians and patients with multiple sclerosis (MS) is essential for patient satisfaction with a given treatment, which could result in therapy persistence. Uwe Zettl and colleagues conducted the study, āComparative evaluation of patientsā…
September 21, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – MS Patients on Oral Gilenya Stick Longer with Treatment in Phase 4 Study A recent study showed that after one year, the majority of multiple sclerosis (MS) patients taking oral Gilenya (fingolimod) therapy stuck with their treatment, while a large proportion of thoseĀ usingĀ injectable disease-modifying drugs did not. The data, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016…